Greg Gibson

Nov 17, 2024 | onlinelibrary.wiley.com | Alka A. Potdar |G. Yu |Greg Gibson |Vivien A. Sheehan

CONFLICT OF INTEREST STATEMENT Vivien A. Sheehan receives research funding from Beam Therapeutics, Pfizer, Novartis, and Agios. Alka A. Potdar and G. Karen Yu are former employees of Pfizer. Supporting Information Filename Description bjh19839-sup-0001-FigS1-S2.docxWord 2007 document , 355 KB Figure S1. Figure S2. bjh19839-sup-0002-TableS1.xlsxExcel 2007 spreadsheet , 248.3 KB Table S1. bjh19839-sup-0003-TableS3.xlsxExcel 2007 spreadsheet , 14.1 KB Table S2.

Jul 30, 2024 | medrxiv.org | Greg Gibson |Sini Nagpal

The authors have declared no competing interest. This work was supported by a grant from the U.S. National Institutes of Health to G.G. (R01-DK119991). Analyses using the UK Biobank Resource were performed under Institutional Review Board approved application number 17984. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Dec 22, 2023 | nature.com | Ken Mautner |Paramita Chatterjee |Kirk A Easley |Greg Gibson |Linda Kippner

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02632-w, published online 2 November 2023. In the version of the article initially published, Table 1 was missing two rows (“VAS – mean baseline” and “KOOS pain – mean baseline”) that have now been inserted in the HTML and PDF versions of the article.

Nov 2, 2023 | nature.com | Ken Mautner |Paramita Chatterjee |Kirk A Easley |Greg Gibson |Linda Kippner

AbstractVarious types of cellular injection have become a popular and costly treatment option for patients with knee osteoarthritis despite a paucity of literature establishing relative efficacy to each other or corticosteroid injections.